We have located links that may give you full text access.
Dexmedetomidine-induced fever and delirium: A case report.
WHAT IS KNOWN AND OBJECTIVE: Dexmedetomidine is a selective alpha-2 agonist used for sedation in the intensive care unit (ICU).
CASE DESCRIPTION: A 41-year-old woman intubated in the ICU and being treated for acute respiratory distress syndrome (ARDS) received dexmedetomidine following successful extubation to treat increasing agitation thought to be secondary to a history of polysubstance abuse. Following initiation of the dexmedetomidine, the patient became febrile as well as increasingly more agitated and delirious. All potential fever or delirium causes were evaluated. Following discontinuation of dexmedetomidine, her fever, agitation and delirium ceased.
WHAT IS NEW AND CONCLUSION: We depict the first known case of dexmedetomidine causing high fevers and delirium.
CASE DESCRIPTION: A 41-year-old woman intubated in the ICU and being treated for acute respiratory distress syndrome (ARDS) received dexmedetomidine following successful extubation to treat increasing agitation thought to be secondary to a history of polysubstance abuse. Following initiation of the dexmedetomidine, the patient became febrile as well as increasingly more agitated and delirious. All potential fever or delirium causes were evaluated. Following discontinuation of dexmedetomidine, her fever, agitation and delirium ceased.
WHAT IS NEW AND CONCLUSION: We depict the first known case of dexmedetomidine causing high fevers and delirium.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app